Effectiveness of JYNNEOS vaccine against diagnosed mpox infection – New York, 2022
summary
What is already known about this topic? The JYNNEOS vaccine was deployed in a national and state vaccination campaign during the 2022 monkeypox (mpox) outbreak. Postexposure prophylaxis and vaccination of persons at highest risk (primarily men who have sex with men) were prioritized. Evidence of vaccine effectiveness (VE) from controlled studies has been limited.What is added by this report? A comparison of men aged =18 years who received a diagnosis of mpox during July 24–October 31 in New York to controls with rectal gonorrhea or primary syphilis, based on systematically collected surveillance data, found adjusted combined 1-dose (received =14 days earlier) or 2-dose VE of 75.7%.
What are the implications for public health practice? These findings support recommended 2-dose JYNNEOS vaccination consistent with CDC and New York State Department of Health guidance.
Full citation:
Rosenberg ES, Dorabawila V, Hart-Malloy R, Anderson BJ, Miranda W, O’Donnell T, Gonzalez CJ, Abrego M, DelBarba C, Tice CJ, McGarry C, Mitchell EC, Boulais M, Backenson B, Kharfen M, McDonald J, Bauer UE (2023). Effectiveness of JYNNEOS vaccine against diagnosed mpox infection – New York, 2022
MMWR Morbidity and Mortality Weekly Report, 72 (20), 559-563. doi: 10.15585/mmwr.mm7220a4. PMCID: PMC10205166.